Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions

A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis

(2018) Jawad Bilal et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain

(2018) Jaime Notario et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study

(2017) Nan-Lin Wu et al.   JOURNAL OF DERMATOLOGY

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)

(2017) Désirée van der Heijde et al.   JOURNAL OF RHEUMATOLOGY

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

(2017) Jerry Bagel et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis

(2016) Ju Yeon Ryoo et al.   ANNALS OF PHARMACOTHERAPY

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

(2016) Jürgen Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study

(2016) K. Yamasaki et al.   BRITISH JOURNAL OF DERMATOLOGY

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study

(2016) Hidemi Nakagawa et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study

(2016) Shinichi Imafuku et al.   JOURNAL OF DERMATOLOGY

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

(2016) Peter C.M. van de Kerkhof et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis

(2016) Y. Umezawa et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

(2015) Himal Lal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

(2014) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

The role of IL-17 in psoriasis

(2014) Mona Malakouti et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

(2014) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Psoriasis prevalence among adults in the United States

(2014) Tara D. Rachakonda et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)

(2014) C. Paul et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

(2014) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma

(2013) William W. Busse et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions

(2013) L. Adelzadeh et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

(2012) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management

(2011) Mauro Viganò et al.   EXPERT OPINION ON BIOLOGICAL THERAPY